Raymond James Financial
GALT icon

Raymond James Financial’s Galectin Therapeutics GALT Stock Holding History

Raymond James Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.8K Buy
14,967
+1,250
+9% +$3.8K ﹤0.01% 5140
2025
Q4 		$57.1K Buy
+13,717
New +$72.2K ﹤0.01% 4998
2025
Q3 		– Sell
-10,550
Closed -$22.3K – 5636
2025
Q2 		$22.3K Sell
10,550
-1,000
-9% -$1.5K ﹤0.01% 5554
2025
Q1 		$14.1K Hold
11,550
– – ﹤0.01% 4752
2024
Q4 		$14.9K Buy
+11,550
New +$27.7K ﹤0.01% 4751

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Raymond James Financial's GALT Position: Q1 2026 in Review

Raymond James Financial increased its Galectin Therapeutics (GALT) stake by 9.1% in Q1 2026, buying an estimated $3.8K and bringing the position to 14,967 shares worth $41.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5140.

Raymond James Financial first reported a position in GALT in Q4 2024 and has held it in 5 quarters since. The position peaked at $57.1K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Raymond James Financial held 14,967 shares of Galectin Therapeutics worth $41.8K as of Q1 2026.
  • Raymond James Financial bought 1,250 Galectin Therapeutics shares in Q1 2026, an estimated $3.8K.
  • Galectin Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5140 holding.
  • Raymond James Financial first reported a position in Galectin Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Raymond James Financial's Galectin Therapeutics position peaked at $57.1K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.